ELITE PHARMACEUTICALS INC /NV/ Quarterly Nonoperating Income (Expense) in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2010 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$13M, a 179% decline year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$21.4M, a 388% decline year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ annual Nonoperating Income (Expense) for 2023 was -$10.3M, a 3432% decline from 2022.
  • Elite Pharmaceuticals Inc /Nv/ annual Nonoperating Income (Expense) for 2022 was $310K, a 74.9% decline from 2021.
  • Elite Pharmaceuticals Inc /Nv/ annual Nonoperating Income (Expense) for 2021 was $1.23M, a 39.5% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$21.4M -$13M -$8.35M -179% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$13M -$3.02M -$2.71M -888% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$10.3M -$1.74M -$1.27M -270% Jan 1, 2024 Mar 31, 2024 10-K 2024-07-01
Q4 2023 -$9.06M -$3.63M -$4.68M -445% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 -$4.38M -$4.66M -$5.1M -1145% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $721K -$305K +$412K +57.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $310K -$469K -$306K -187% Jan 1, 2023 Mar 31, 2023 10-K 2024-07-01
Q4 2022 $616K $1.05M +$598K +132% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 $17.5K $446K +$69.2K +18.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$51.7K -$717K -$1.29M -226% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $1.23M -$163K Jan 1, 2022 Mar 31, 2022 10-K 2023-06-29
Q4 2021 $452K -$559K -55.3% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 $376K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $569K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q4 2020 $1.01M Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q1 2018 $4.33M -$203K -$207K Jan 1, 2018 Mar 31, 2018 10-K 2018-06-14
Q4 2017 $4.54M $517K -$1M -66% Oct 1, 2017 Dec 31, 2017 10-K 2018-06-14
Q3 2017 $5.54M $3.95M -$1.5M -27.5% Jul 1, 2017 Sep 30, 2017 10-K 2018-06-14
Q2 2017 $7.04M $73K -$2.26M -96.9% Apr 1, 2017 Jun 30, 2017 10-K 2018-06-14
Q1 2017 $9.3M $4K* -$7.4M Jan 1, 2017 Mar 31, 2017 10-K 2018-06-14
Q4 2016 $16.7M $1.52M +$11M Oct 1, 2016 Dec 31, 2016 10-K 2018-06-14
Q3 2016 $5.67M $5.44M +$3.36M +161% Jul 1, 2016 Sep 30, 2016 10-K 2018-06-14
Q2 2016 $2.31M $2.33M -$4.81M -67.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-06-14
Q1 2016 $7.11M $7.41M +$8.31M Jan 1, 2016 Mar 31, 2016 10-K 2018-06-14
Q4 2015 -$1.19M -$9.52M -$19.5M -195% Oct 1, 2015 Dec 31, 2015 10-K 2018-06-14
Q3 2015 $18.3M $2.09M -$8.22M -79.8% Jul 1, 2015 Sep 30, 2015 10-K 2018-06-14
Q2 2015 $26.5M $7.14M +$4.8M +205% Apr 1, 2015 Jun 30, 2015 10-K 2018-06-14
Q1 2015 $21.7M -$898K +$30.8M +97.2% Jan 1, 2015 Mar 31, 2015 10-K 2017-06-14
Q4 2014 -$9.03M $9.97M +$9.8M +5599% Oct 1, 2014 Dec 31, 2014 10-K 2017-06-14
Q3 2014 -$18.8M $10.3M +$17.2M Jul 1, 2014 Sep 30, 2014 10-K 2017-06-14
Q2 2014 -$36M $2.34M +$243K +11.6% Apr 1, 2014 Jun 30, 2014 10-K 2017-06-14
Q1 2014 -$36.3M -$31.7M -$33.2M -2173% Jan 1, 2014 Mar 31, 2014 10-K 2016-06-15
Q4 2013 -$3.09M $175K -$9.46M -98.2% Oct 1, 2013 Dec 31, 2013 10-K 2016-06-15
Q3 2013 $6.37M -$6.89M -$8.45M -540% Jul 1, 2013 Sep 30, 2013 10-K 2016-06-15
Q2 2013 $14.8M $2.1M +$12.1M Apr 1, 2013 Jun 30, 2013 10-K 2016-06-15
Q1 2013 $2.7M $1.53M +$8.41M Jan 1, 2013 Mar 31, 2013 10-K 2014-06-30
Q4 2012 -$5.71M $9.64M +$445K +4.85% Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-14
Q3 2012 -$6.16M $1.57M -$12.9M -89.2% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-14
Q2 2012 $6.78M -$10M +$20.4M +67% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 -$13.6M -$6.88M +$9.3M +57.5% Jan 1, 2012 Mar 31, 2012 10-K 2013-06-21
Q4 2011 -$22.9M $9.19M +$3.34M +57% Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-14
Q3 2011 -$26.2M $14.5M +$12.5M +625% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 -$38.7M -$30.4M -$25.7M -550% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-14
Q1 2011 -$13M -$16.2M Jan 1, 2011 Mar 31, 2011 10-K 2012-06-29
Q4 2010 $5.86M Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-14
Q3 2010 $2M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 -$4.67M Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-08-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.